OXFORD, UK--Oxford Glyco-sciences's stock price climbed nearly 15 percent last week when it was awarded a US patent for high-throughput protein screening technology. The patent describes technologies for separating biological samples into 2-dimensional arrays, and then generating digitized images of the resulting patterns. Methods for quantitatively measuring proteins and protein changes exhibited between different biological samples are also provided in the patent.
Finally, the invention covers methods for automation and robotics to examine sample pattern differences, and to select specific proteins for sequence identification by methods such as mass spectrophotometry.
Oxford is using the technology in a joint venture with Incyte Genomics to create a proteomics database.
The company has also filed patent applications on proteins found within and on the surface membranes of breast cancer cells using its proprietary proteomic technologies and bioinformatics software. The company's chief scientific officer, Raj Parekh, claimed that the work represents the first time a "proteomics study of this breadth has been performed in any disease."